Study guide

Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections

Key Takeaways Explain This Topic AI

Early-onset sepsis (<72 hours of life) arises from ascending or vertical intrapartum transmission (Group B Streptococcus and Escherichia coli), while late-onset sepsis (≥72 hours) reflects horizontal nosocomial or community pathogen acquisition.

For neonatal categorical risk assessment, adequate GBS intrapartum prophylaxis is at least 4 hours of intravenous penicillin, ampicillin or cefazolin. Shorter exposure can still help; do not delay necessary obstetric care to complete 4 hours.

Empiric early-onset sepsis therapy commonly uses IV ampicillin plus gentamicin. Late-onset regimens depend on neonatal-unit versus community presentation. Ceftriaxone has important neonatal restrictions involving prematurity, bilirubin binding and IV calcium; use the applicable national pathway.

CMV is the most common congenital viral infection, classically causing periventricular calcifications, microcephaly and progressive sensorineural hearing loss. Significant symptomatic disease warrants 6 months of valganciclovir, which can modestly improve longer-term hearing and developmental outcomes; monitor for neutropenia.

Neonatal HSV, usually acquired around delivery, presents as skin-eye-mouth (SEM), CNS or disseminated disease. Start IV aciclovir promptly (60 mg/kg/day divided 8-hourly with normal renal function): 14 days for SEM and at least 21 days for CNS/disseminated disease; confirm CSF clearance before ending CNS treatment.

Last updated: November 2026

Neonatal Infections: Sepsis Syndromes and Congenital Pathogens

Neonates possess an immature immune system characterized by deficient complement activity, impaired neutrophil chemotaxis, low concentrations of endogenous immunoglobulins (with preterm infants lacking transplacental maternal IgG acquired primarily during the third trimester), and naive cell-mediated immunity. Consequently, systemic bacterial infections and congenital intrauterine pathogens carry high mortality and lifelong neurodevelopmental morbidity.

Early-Onset vs. Late-Onset Neonatal Sepsis

Systemic neonatal bacterial infections are categorized according to the timing of clinical presentation, reflecting fundamentally different modes of transmission, microbial etiologies, and clinical courses.

  • Feature Early-Onset Sepsis (EOS) Late-Onset Sepsis (LOS)
  • Timing of Onset <72 hours of life (frequently within first 24-48 hours) ≥72 hours to 90 days of life

Transmission Mode Vertical transmission from maternal genital tract (ascending infection or during vaginal delivery) Horizontal transmission (nosocomial NICU environment, vascular lines, endotracheal tubes, or community)

Predominant Pathogens Group B Streptococcus (GBS) (~40-50%), Escherichia coli (~25-30%), Listeria monocytogenes , Enterococcus spp. Coagulase-negative Staphylococci (CoNS) (~50%), Staphylococcus aureus , Klebsiella , Pseudomonas , Serratia , Candida spp.

Primary Risk Factors Prematurity, maternal GBS colonization, prolonged rupture of membranes (≥18 hours), maternal chorioamnionitis Extreme prematurity/VLBW, central venous lines, mechanical ventilation, parenteral nutrition, broad-spectrum antibiotics

Typical Clinical Course Fulminant systemic bacteremia, pneumonia, septic shock, rapid respiratory deterioration Insidious or acute bacteremia, central line-associated bloodstream infection (CLABSI), meningitis, necrotizing enterocolitis

Empiric Regimen IV Ampicillin + IV Gentamicin Neonatal-unit LOS: IV Flucloxacillin (or Vancomycin) + IV Gentamicin/Amikacin; broaden according to local resistance. Community admission: follow the age-specific sepsis/meningitis pathway

Group B Streptococcus (GBS) and Intrapartum Antibiotic Prophylaxis

Streptococcus agalactiae (Group B Streptococcus) is a Gram-positive diplococcus colonizing the gastrointestinal and genitourinary tracts of 15% to 30% of pregnant women . Without intervention, 50% of infants born to colonized mothers become colonized, and 1% to 2% develop invasive early-onset GBS disease (sepsis, pneumonia, or meningitis).

Maternal Screening and Indications for Prophylaxis

GBS prevention follows national policy: the UK does not recommend universal screening ; some European programmes use vaginal-rectal cultures at 35–37 weeks , while US ACOG uses 36+0–37+6 weeks . In culture-based/risk-based pathways, intrapartum antibiotic prophylaxis (IAP) is indicated during labour or after membrane rupture for:

  • Positive maternal vaginal-rectal GBS culture during current pregnancy
  • Documented GBS bacteriuria or urinary tract infection at any point during current pregnancy
  • Previous infant delivered with invasive GBS disease

Unknown GBS colonization status at onset of labor combined with any intrapartum risk factor:

  • Preterm delivery (<37 weeks gestation)
  • Prolonged rupture of membranes (PROM) ≥18 hours
  • Maternal intrapartum fever ≥38.0°C (100.4°F)

GBS-specific IAP is not required for prelabour caesarean birth with intact membranes , even with a positive culture. Suspected intra-amniotic infection requires appropriate broad-spectrum maternal treatment, rather than GBS prophylaxis alone.

Recommended IAP Regimens

First-Line : Intravenous Benzylpenicillin (Penicillin G) : 5 million units IV loading dose, followed by 2.5 to 3.0 million units IV every 4 hours until delivery; OR Intravenous Ampicillin : 2 g IV loading dose, then 1 g IV every 4 hours until delivery.

Adequacy for Neonatal Risk Assessment : ≥4 hours of IV penicillin, ampicillin or cefazolin constitutes adequate IAP in categorical neonatal algorithms. Shorter exposure still offers benefit; do not delay necessary obstetric interventions solely to reach 4 hours.

Penicillin Allergy Regimens :

Low risk for anaphylaxis (e.g., maculopapular rash): Intravenous Cefazolin (2 g loading, then 1 g q8h).

High risk for anaphylaxis (e.g., bronchospasm, angioedema, urticaria): If GBS isolate is known susceptible, Intravenous Clindamycin (900 mg q8h). If resistant or susceptibility unknown, Intravenous Vancomycin (ACOG: 20 mg/kg q8h, maximum 2 g per dose , with dosing based on weight and renal function).

Note

The Kaiser Permanente Neonatal Sepsis Calculator : In late preterm and term infants (≥34 weeks), modern pediatric centers utilize the multivariate Sepsis Calculator to estimate individualized early-onset sepsis risk based on objective maternal factors (GBS status, maximum maternal temperature, duration of ruptured membranes, type of IAP) and the infant's real-time clinical examination. This approach safely reduces invasive blood cultures and unnecessary empiric antibiotic exposure by up to 50%.

Diagnostic Evaluation of Suspected Neonatal Sepsis

The clinical signs of neonatal sepsis are notoriously subtle, non-specific, and easily confused with transitional adaptation or metabolic instability:

Thermal Instability : Hypothermia (<36.5°C) is far more common than fever (>37.5°C), particularly in premature infants.

Respiratory Distress : Tachypnea, grunting, intercostal retractions, increased oxygen requirement, or new-onset unexplained apnea.

Hemodynamic Instability : Tachycardia, delayed capillary refill time (>3 seconds), weak peripheral pulses, hypotension, cool/mottled extremities.

Neurological Depression : Lethargy, irritability, hypotonia, weak suck, high-pitched cry, or seizures.

Gastrointestinal Dysfunction : Feeding intolerance, abdominal distension, vomiting, or bilious gastric aspirates.

Laboratory Workup Protocol

Blood Culture : The absolute gold standard. A minimum volume of 1.0 mL of blood must be inoculated into an aerobic blood culture bottle prior to administering antibiotics. Volumes <0.5 mL yield unacceptably high false-negative rates due to low-level bacteremia (1-10 CFU/mL).

Complete Blood Count with Differential :

Leukopenia (total WBC <5,000/µL) has higher specificity for sepsis than leukocytosis (WBC >25,000-30,000/µL).

Immature to Total Neutrophil Ratio (I:T Ratio) : Calculated as Bands + Metamyelocytes + Myelocytes Total Neutrophils \frac{\text{Bands + Metamyelocytes + Myelocytes}}{\text{Total Neutrophils}} Total Neutrophils Bands + Metamyelocytes + Myelocytes ​ . An I:T ratio >0.20 reflects a pathological left shift indicating bone marrow neutrophil release.

Thrombocytopenia (platelet count <100,000/µL): Frequently accompanies severe sepsis and disseminated intravascular coagulation (DIC).

Inflammatory Biomarkers (C-Reactive Protein and Procalcitonin) :

C-Reactive Protein (CRP) : Synthesized by hepatocytes in response to IL-6. CRP rises slowly, beginning 10 to 12 hours after infectious insult and peaking at 36 to 48 hours. A normal CRP at symptom onset cannot exclude sepsis . Serial reassuring CRP results can support stopping treatment, but must not determine the decision alone . Interpret them with blood cultures, the initial likelihood of infection and the infant’s clinical course.

Procalcitonin (PCT) : Rises faster (2-4 hours). However, neonates experience a physiological surge in procalcitonin during the first 48 hours after birth, requiring gestational age- and hour-specific cutoffs.

Lumbar Puncture (LP) :

Perform when safe if neonatal infection is strongly suspected or there are signs of meningitis; do not wait for a positive blood culture. Meningitis may occur with a negative blood culture.

Also consider LP after a positive blood culture or poor treatment response if not done initially. Stabilise respiratory/circulatory compromise or uncontrolled seizures first; do not delay urgent antibiotics for an unsafe LP.

Urine Culture : Follow the care setting. NICE advises against routine urine culture for EOS or for LOS in neonatal units, but recommends it for suspected LOS outside neonatal units. Obtain an appropriate uncontaminated specimen, usually by catheterisation or suprapubic aspiration in an ill neonate. Urinary infection is uncommon in EOS, so initial investigation focuses on blood cultures and clinical assessment.

  • Empiric Antimicrobial Regimens Suspected Neonatal Sepsis
  • │
  • ├─────────────────────────────────────────┐
  • ▼ ▼
  • Early-Onset Sepsis (<72h) Neonatal-Unit LOS (≥72h)
  • Vertical Pathogens (GBS, E. coli, Listeria) Nosocomial / Catheter Pathogens (CoNS, S. aureus, GNR)
  • │ │
  • ▼ ▼
  • IV AMPICILLIN IV FLUCLOXACILLIN (or VANCOMYCIN)
  • + +
  • IV GENTAMICIN IV GENTAMICIN / AMIKACIN
  • (Synergistic bactericidal GBS kill; (Add Meropenem / Ceftazidime if
  • covers Gram-negative coliforms) Pseudomonas or resistant GNR suspected)
  • │ │
  • ▼ ▼
  • Reassess EOS at 36–48 hours: If invasive Candida suspected

Negative culture + low initial suspicion (VLBW, central line, platelets plummeting):

  • + well infant + reassuring CRP trend ──► Add AMPHOTERICIN B
  • ──► STOP; otherwise reassess ongoing need
  • Early-Onset Sepsis Empiric Therapy

IV Ampicillin + IV Gentamicin : Ampicillin provides robust coverage against Streptococcus agalactiae , Listeria monocytogenes , and susceptible enterococci. Gentamicin provides broad coverage against Gram-negative Enterobacteriaceae ( E. coli , Klebsiella ) and acts synergistically with ampicillin to accelerate bacterial killing of GBS.

Community-Onset Infection and Ceftriaxone Restrictions : NICE uses a third-generation cephalosporin plus ampicillin/amoxicillin for Listeria coverage in young infants presenting from home. For neonates, NICE permits ceftriaxone only above 40 weeks corrected gestation without IV calcium; otherwise use cefotaxime, while also respecting the contraindications below. Ceftriaxone is contraindicated in premature neonates up to 41 weeks postmenstrual age, neonates with impaired bilirubin binding (including jaundice), and neonates ≤28 days needing or expected to need IV calcium. Bilirubin displacement can increase neurotoxicity risk; calcium-ceftriaxone precipitation can cause fatal organ injury. Follow the national sepsis/meningitis pathway and local resistance data.

Antibiotic Stewardship : Stop empiric EOS antibiotics at 36–48 hours when cultures are negative, initial suspicion was low, the infant is well and inflammatory-marker trends are reassuring. NICE specifies 36 hours for EOS and consideration at 48 hours for LOS . Strongly suspected culture-negative infection requires continued assessment and treatment; CRP alone cannot decide cessation.

  • Treatment Durations for Confirmed Infection
  • Uncomplicated bacteremia: 7 to 10 days
  • Group B Streptococcal meningitis: 14 days

Gram-negative bacillary meningitis ( E. coli ): 21 days (or at least 14 days after documentation of CSF sterilization)

Congenital TORCH Infections

The TORCH complex encompasses transplacental and perinatal infections caused by Toxoplasmosis , Other (Syphilis, Varicella, Parvovirus B19), Rubella , Cytomegalovirus (CMV) , and Herpes Simplex Virus (HSV) . While each pathogen produces distinct clinical hallmarks, they share overlapping features of intrauterine growth restriction (IUGR), hepatosplenomegaly, microcephaly, thrombocytopenia, and jaundice.

Pathogen Transmission & Risk Classic Clinical Triad / Features Diagnostic Confirmation Evidence-Based Therapy

Toxoplasma gondii Maternal ingestion of undercooked cyst-containing meat or cat feces; transmission risk increases with gestational age Sabin Tetrad : Chorioretinitis (macular scar), Hydrocephalus , Diffuse parenchymal intracranial calcifications , Convulsions Infant serum IgM/IgA; Toxoplasma PCR in amniotic fluid/CSF/blood Pyrimethamine + Sulfadiazine + Folinic acid for 12 months

Rubella Virus Maternal primary infection in 1st trimester (>80% fetal defect rate; rare after 20 weeks) Gregg Triad : Cataracts (microphthalmia), Sensorineural hearing loss , Cardiac defects (Patent Ductus Arteriosus, Pulm. artery stenosis); "Blueberry muffin" rash, celery-stalk metaphyses Maternal/infant rubella IgM; viral RNA PCR Supportive care; Prevention via MMR vaccine (live, given prior to pregnancy)

Cytomegalovirus (CMV) Most common congenital viral infection (0.5-1% live births); maternal primary or reactivation Periventricular intracranial calcifications , microcephaly, Sensorineural hearing loss (progressive), chorioretinitis, petechial rash CMV PCR within 21 days ; confirm a positive saliva result with urine PCR Significant symptomatic disease: valganciclovir 16 mg/kg/dose BID for 6 months ; monitor ANC. Asymptomatic infection alone does not require treatment

Herpes Simplex Virus (HSV) Perinatal intrapartum contact (85%) during delivery via infected genital secretions; HSV-2 > HSV-1 Three forms: SEM (Skin, Eye, Mouth vesicles); CNS (encephalitis, seizures, lethargy); Disseminated (septic shock, liver failure, DIC) HSV DNA PCR of CSF, blood, and conjunctival/mucosal/vesicle swabs High-dose IV Aciclovir (60 mg/kg/day divided q8h): 14 days (SEM) or at least 21 days (CNS/disseminated); for CNS disease, confirm negative CSF PCR before stopping, then oral suppression for 6 months

Treponema pallidum (Syphilis) Transplacental spirochetal transmission at any gestational age; risk highest in untreated early syphilis Early: "Snuffles" (bloody rhinitis), desquamating palm/sole rash, Wimberger sign (metaphyseal erosion), periostitis. Late: Hutchinson triad Maternal/infant nontreponemal (RPR/VDRL) + treponemal (TPPA/FTA-ABS); Infant RPR ≥4-fold maternal titer Aqueous Crystalline Penicillin G IV for 10 days (50,000 U/kg/dose q12h days 1-7, then q8h)

  • Clinical Distinctions Among TORCH Infections INTRACRANIAL CALCIFICATIONS PATTERN
  • ┌────────────────────────────────────────┐
  • │ │
  • ▼ ▼
  • PERIVENTRICULAR DIFFUSE PARENCHYMAL
  • (Lining the lateral ventricles) (Scattered across cortex & basal ganglia)
  • │ │
  • ▼ ▼
  • CONGENITAL CMV CONGENITAL TOXOPLASMOSIS
  • (+ Microcephaly, SNHL) (+ Hydrocephalus, Chorioretinitis)
  • Congenital Cytomegalovirus (CMV): Detailed Management

CMV is the leading non-genetic cause of sensorineural hearing loss and neurodevelopmental disability in developed nations. Approximately 85% to 90% of infected neonates are asymptomatic at birth ; however, 10% to 15% of these asymptomatic infants will develop progressive sensorineural hearing loss during childhood.

The 21-Day Diagnostic Window : Test urine or saliva for CMV DNA within the first 21 days of life ; a positive saliva result requires confirmatory urine PCR because breast-milk contamination can cause false positives. Testing beyond day 21 cannot distinguish congenital infection from postnatally acquired CMV (e.g., through maternal breast milk or transfusion), which does not carry the same neurodevelopmental risks.

Pharmacological Treatment : In infants with symptomatic congenital CMV disease involving the central nervous system (microcephaly, abnormal neuroimaging, chorioretinitis, hearing loss) or severe organ involvement, oral valganciclovir (16 mg/kg/dose twice daily) administered for 6 months can modestly improve longer-term hearing and neurodevelopmental outcomes; it does not guarantee hearing preservation. The major dose-limiting adverse effect is neutropenia , requiring regular monitoring of absolute neutrophil counts (ANC).

Neonatal Herpes Simplex Virus (HSV): Clinical Syndromes and Pitfalls

Neonatal HSV infection presents in three clinically distinct forms, typically appearing between the first and third weeks of life:

Skin, Eye, and Mouth (SEM) Disease (45%) : Presents at 1 to 2 weeks with localized vesicular lesions on an erythematous base, keratoconjunctivitis, and oral ulcers. Without treatment, >70% of SEM cases progress to CNS or disseminated disease.

Central Nervous System (CNS) Disease (30%) : Presents at 2 to 3 weeks with lethargy, irritability, temperature instability, focal seizures, and CSF pleocytosis (elevated protein and lymphocytic pleocytosis). Critical Exam Fact : Up to 30% to 40% of neonates with CNS HSV disease NEVER develop skin vesicles!

Disseminated Disease (25%) : Presents at 9 to 11 days with fulminant septic shock, multiorgan failure, disseminated intravascular coagulation (DIC), severe hepatitis with profound coagulopathy, and pneumonitis. Mortality exceeds 30% even with aggressive treatment.

Warning

Empiric Aciclovir in Neonatal Sepsis : Any infant in the first 4 weeks of life presenting with unexplained seizures, lymphocytic CSF pleocytosis, fulminant hepatitis, or clinical sepsis unresponsive to standard antibacterial therapy must be started immediately on high-dose intravenous aciclovir (60 mg/kg/day divided every 8 hours) while awaiting viral diagnostic PCR results.